The 1.2-million-dollar injection of the anti-cancer drug known as Akirenzai Injection belongs to a type of CAR-T therapy, whose main indications are certain relapsed or refractory large B-cell lymphomas. Akirense injection belongs to chimeric antigen receptor cell therapy, also known as CAR-T therapy, and is the first CAR-T therapy approved and marketed in China. Its currently approved indications are: large B-cell lymphoma that has relapsed or metastasized after previous second-line or higher systemic therapy. There are some risks associated with Achille’s Rense injection as an immunotherapy, such as cytokine storm, CAR-T cell-associated encephalopathy syndrome, and exacerbation of infections caused by immune disorders. It is not suitable for patients with severe myelosuppression, severe anemia, severe hepatic or renal insufficiency, allergy to drug components, or in the acute exacerbation of the disease. As a new anticancer drug with clear indications and contraindications, Akirensai Injection has a complicated preparation process and a very high price, so it is recommended that patients consult a professional doctor to decide whether to use it according to their conditions.